Member Info for KanakJoshi

Interactive Investor is quoting 2.95 to SELL

What is this ….

09-Jun-26 15:07:47 2.90 21 Sell* 0.61

…?

@ bunsenburner123, I hope you didn’t lose too many £££s on your other investment. I am waiting for +5p here to move into profit on this holding. As you may recall I did buy at 2.765 last week, so my average price is lower than it used to be. I am in this for the long term because the CEO has a good track record.

As always, DYOR, GLA, RTFM, etc.

05-Jun-26 14:56:44 2.60 750,000 Sell* 19.50k

…and the price held strong. As I said in the title of the tread … Sell, they will take them all.

Sells <£100 are T212 day traders working on a few £’s here and there. Nothing wrong with taking a profit, but also not too much to worry about. All the power to the people who can make money trading on T212; that’s what we are all here to do. It’s more difficult to trade small volumes if it costs £3.99 per trade on other platforms.

GLA to all day traders and LTHs, a profit is a profit, big or small.

I think anything at +2.70 is a buy. The spread is wide, and this may be due to some platforms asking +2.8 to buy.

I think some of the “no commission” platforms make their money by offering a wide spread, and this can throw the buy-sell volumes.

IMHO, DYOR, GLA, etc.

500,000 2.765 08:34:48 is me and it’s not a SELL 😉

I notice that the SELLs are in £100s and the BUYs are in £1000 !!!!

I just did a quick test to sell a whole load of MPAL, on the price drop, and guess what? They will take them all!!!

If they are willing to take the sell order, there is a buy order waiting to pick them up.

Last week even a small sell was going to NT, and not giving an instant price.

Hi, I picked up on that statement too. Imagine if Boots outsource to us; it would be more cost effective for them !!!!

Has a buy for 2.70 just gone through ???

Great RNS and there is no mention of April and May numbers !!! Can’t wait to see what the Pharmacy update will be for those months. There could be a stonker of an RNS coming with the April, May and June (next quarter) operational update.

Retatrutide is an investigational once-weekly injectable medication developed by Eli Lilly that is currently undergoing Phase 3 clinical trials. Often dubbed "Triple G," it is a groundbreaking medication that activates three hormone receptors: GLP-1, GIP, and glucagon.

Unlike current weight-loss medications (such as Wegovy or Zepbound) that target one or two receptors, retatrutide's triple-agonist design tackles weight loss and blood sugar regulation on three distinct fronts:

•GLP-1 receptor activation: Suppresses appetite and slows down digestion, helping you feel fuller for longer.

•GIP receptor activation: Further reduces food intake and plays a key role in fat metabolism.

•Glucagon receptor activation: Stimulates energy expenditure, causing the body to break down stored fat and burn energy more efficiently.

Don’t we also have some kind of integration with health care monitoring devices?

In addition, the government is committing to tackle obesity with the GLP-1 program. If MPAL can get ahead of the curve with this initiative with their AI and pharmacy dispensaries we should see a rapid increase in the reported numbers.

Looking for a rise now that ATM is exhausted and larger volume of shares will have to be bought on the open market. Holding and hoping for 6.5p and above.

MPAL has been trading since late August 2025 and there may be scepticism about the model and profitability. We will have to wait for the Accounts and hopefully profit and dividends before this shows up on many people’s radar. I am hoping and holding for 6.5p at the moment. GLA.

ATM shares go direct to the buyer and the proceeds go to the company. The last tranche of ATM shares were sold at a higher price than where we are currently; the buyer(s) has confidence in putting that much into the company.

ATM has to be reported before they are listed and then traded. From Jan 16th RNS … “ The Company has raised further gross proceeds of approximately £378,870 via the ATM facility through the issue of 6,200,000 new ordinary shares ("ATM Shares") at an average price of 6.11p per ATM Share.”

From 14,757 to 36,951 items within a few months. Upgrade to servers, robotics and LLY contract all add to the positive news from MPAL.